한글목차

세계의 호흡기 의약품 시장 규모는 2024년에 512억 3,100만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 5.5%로 성장하여 2031년까지 746억 4,500만 달러로 확대될 것으로 예측됩니다.

본 보고서는 최근 호흡기 의약품에 대한 관세 조정과 국제적인 전략적 대응책에 대해 국경 간 산업 발자국, 자본 배분 패턴, 지역 경제의 상호의존성, 공급망 재구축 등의 관점에서 종합적인 평가를 제공합니다.

호흡기 의약품은 천식, 만성기관지염, 만성폐쇄성폐질환(COPD), 폐렴 등 호흡기질환을 완화, 치료, 예방하기 위해 사용되는 다양한 의약품을 총칭하는 용어입니다. 2024년 세계 호흡기 의약품 생산량은 약 38억5100만 개, 세계 평균 시장 가격은 개당 약 13.3달러였습니다.

전 세계적으로 호흡기질환 환자 수는 지속적으로 증가하고 있으며, COPD, 천식, 만성 호흡기질환이 주요 환자층을 형성하며 의약품에 대한 강력한 수요를 견인하고 있습니다. 각국 정부와 규제 당국은 혁신적인 의약품 개발, 흡입제 생물학적 동등성 평가, 만성질환 관리를 지원하는 정책을 도입하여 신약 및 개량신약의 시장 출시를 가속화하고 있습니다. 주요 제약회사의 연례 보고서에 따르면, 흡입 요법과 생물학적 제제는 전년 대비 큰 폭의 성장세를 보이고 있으며, R&D 투자와 특허 포트폴리오가 장기적인 시장 확장을 확고히 하고 있습니다. 증권사 조사에 따르면, 디지털 헬스 플랫폼과의 통합과 맞춤형 치료를 위한 원격 모니터링이 향후 5년간 시장 침투율을 크게 높일 수 있을 것으로 전망하고 있습니다. 대기오염 악화, 고령화, 만성질환 관리의 필요성이 시장 성장을 뒷받침하고 있으며, 혁신적 의약품과 고부가가치 제제가 주요 차별화 요소로 작용하고 있습니다.

호흡기 의약품 분야는 높은 연구개발 비용, 긴 개발 주기, 엄격한 규제 요건에 직면해 있습니다. 연례 보고서에서 원자재 가격의 변동성과 수입 중간체 및 원료의약품에 대한 의존도가 생산 리스크를 증가시키고 있다고 지적했습니다. 리베이트 목록 개정 및 수량 기반 조달 정책은 제네릭 의약품의 수익률을 압박할 수 있는 반면, 하이엔드 혁신 제품은 환자의 복약 순응도와 임상적 증거에 의존합니다. 국가별 규제 차이로 인해 국경 간 시장 진입이 복잡해지고 있습니다. 치열한 경쟁 환경 속에서 신제품은 임상적 우위, 환자 경험의 이점, 차별화된 서비스를 입증하여 재구매와 시장 점유율을 확보해야 합니다.

최종사용자의 요구는 정밀성, 개인화, 전주기 관리로 이동하고 있습니다. 재택 만성질환 관리 및 원격 헬스케어 플랫폼의 성장으로 흡입 요법, 스마트 분무기, 개인별 맞춤 투약 약물의 채택이 증가하고 있습니다. 의료 기관에서는 효과 추적 및 복약 순응도 모니터링을 위해 전자의무기록, 원격 모니터링, 분석 플랫폼과 통합된 제품이 선호되고 있습니다. 중개 분석에 따르면, 병용요법, 조절 가능한 용량, 디지털 관리 기능이 주요 차별화 요소이며, 데이터 분석 및 원격 추적관찰은 만성질환 관리 및 환자 교육에 있어 장기적인 가치를 실현할 수 있습니다.

이 보고서는 호흡기 의약품 세계 시장에 대해 총 판매량, 매출액, 가격, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

이 보고서는 2024년을 기준 연도, 2020년에서 2031년까지의 기간 동안 과거 데이터와 예측 데이터를 포함하여 판매량(백만 단위) 및 매출액(백만 달러)으로 호흡기 약물 시장의 규모, 추정치 및 예측치를 제시합니다. 정량적, 정성적 분석을 통해 독자들이 사업 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장 내 자사 위치 분석, 호흡기 의약품에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Vertex
• Roche
• Novartis
• Teva
• Chiesi
• Mylan
• Sumitomo Dainippon
• Merck
• Beximco

유형별 부문

• 흡입제 및 점비 스프레이
• 경구
• 기타

용도별 부문

• 병원
• 드럭스토어

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Respiratory Drug was estimated to be worth US$ 51231 million in 2024 and is forecast to a readjusted size of US$ 74645 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Respiratory Drug cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Respiratory drug is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. In 2024, global Respiratory drug production reached approximately 3851 m units, with an average global market price of around US$ 13.3 perunit.

The global population of respiratory disease patients continues to grow, with COPD, asthma, and chronic respiratory conditions representing a substantial patient base, driving strong demand for medications. Governments and regulators are introducing policies to support innovative drug development, bioequivalence evaluation of inhaled formulations, and chronic disease management, accelerating the launch of new drugs and improved formulations. Annual reports of leading pharmaceutical companies indicate significant year-on-year growth in inhaled therapies and biologics, with R&D investment and patent portfolios securing long-term market expansion. Brokerage research suggests that integration with digital health platforms and remote monitoring for personalized therapy could significantly increase market penetration over the next five years. Rising air pollution, aging populations, and chronic disease management needs sustain market growth, with innovative drugs and high-value formulations as key differentiators.

The respiratory drug sector faces high R&D costs, long development cycles, and strict regulatory requirements. Annual reports highlight that raw material price volatility and reliance on imported intermediates or APIs increase production risks. Adjustments to reimbursement lists and volume-based procurement policies may compress margins for generic drugs, while high-end innovative products depend on patient adherence and clinical evidence. Regulatory differences across countries complicate cross-border market entry. Intense competition requires new products to demonstrate clinical advantage, patient experience benefits, and differentiated services to secure repeat purchases and market share.

End-user demand is shifting toward precision, personalization, and full-cycle management. The growth of home chronic disease management and remote healthcare platforms is driving increased adoption of inhaled therapies, smart nebulizers, and personalized dosage medications. Healthcare institutions favor products integrated with electronic medical records, remote monitoring, and analytics platforms for efficacy tracking and adherence monitoring. Brokerage analyses indicate that combination therapies, adjustable dosages, and digital management capabilities will become key differentiators, while data analytics and remote follow-up enable long-term value in chronic disease management and patient education.

This report aims to provide a comprehensive presentation of the global market for Respiratory Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Respiratory Drug by region & country, by Type, and by Application.

The Respiratory Drug market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Respiratory Drug.

Market Segmentation

By Company

• GSK
• AstraZeneca
• Boehringer Ingelheim
• Vertex
• Roche
• Novartis
• Teva
• Chiesi
• Mylan
• Sumitomo Dainippon
• Merck
• Beximco

Segment by Type

• Inhalable & Nasal Spray
• Oral
• Others

Segment by Application

• Hospital
• Drugs Store

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Respiratory Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Respiratory Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Respiratory Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Respiratory Drug Product Introduction
• 1.2 Global Respiratory Drug Market Size Forecast
  • 1.2.1 Global Respiratory Drug Sales Value (2020-2031)
  • 1.2.2 Global Respiratory Drug Sales Volume (2020-2031)
  • 1.2.3 Global Respiratory Drug Sales Price (2020-2031)
• 1.3 Respiratory Drug Market Trends & Drivers
  • 1.3.1 Respiratory Drug Industry Trends
  • 1.3.2 Respiratory Drug Market Drivers & Opportunity
  • 1.3.3 Respiratory Drug Market Challenges
  • 1.3.4 Respiratory Drug Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Respiratory Drug Players Revenue Ranking (2024)
• 2.2 Global Respiratory Drug Revenue by Company (2020-2025)
• 2.3 Global Respiratory Drug Players Sales Volume Ranking (2024)
• 2.4 Global Respiratory Drug Sales Volume by Company Players (2020-2025)
• 2.5 Global Respiratory Drug Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Respiratory Drug Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Respiratory Drug Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Respiratory Drug
• 2.9 Respiratory Drug Market Competitive Analysis
  • 2.9.1 Respiratory Drug Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Respiratory Drug Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Respiratory Drug as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Inhalable & Nasal Spray
  • 3.1.2 Oral
  • 3.1.3 Others
• 3.2 Global Respiratory Drug Sales Value by Type
  • 3.2.1 Global Respiratory Drug Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Respiratory Drug Sales Value, by Type (2020-2031)
  • 3.2.3 Global Respiratory Drug Sales Value, by Type (%) (2020-2031)
• 3.3 Global Respiratory Drug Sales Volume by Type
  • 3.3.1 Global Respiratory Drug Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Respiratory Drug Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Respiratory Drug Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Respiratory Drug Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Drugs Store
• 4.2 Global Respiratory Drug Sales Value by Application
  • 4.2.1 Global Respiratory Drug Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Respiratory Drug Sales Value, by Application (2020-2031)
  • 4.2.3 Global Respiratory Drug Sales Value, by Application (%) (2020-2031)
• 4.3 Global Respiratory Drug Sales Volume by Application
  • 4.3.1 Global Respiratory Drug Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Respiratory Drug Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Respiratory Drug Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Respiratory Drug Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Respiratory Drug Sales Value by Region
  • 5.1.1 Global Respiratory Drug Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Respiratory Drug Sales Value by Region (2020-2025)
  • 5.1.3 Global Respiratory Drug Sales Value by Region (2026-2031)
  • 5.1.4 Global Respiratory Drug Sales Value by Region (%), (2020-2031)
• 5.2 Global Respiratory Drug Sales Volume by Region
  • 5.2.1 Global Respiratory Drug Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Respiratory Drug Sales Volume by Region (2020-2025)
  • 5.2.3 Global Respiratory Drug Sales Volume by Region (2026-2031)
  • 5.2.4 Global Respiratory Drug Sales Volume by Region (%), (2020-2031)
• 5.3 Global Respiratory Drug Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Respiratory Drug Sales Value, 2020-2031
  • 5.4.2 North America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Respiratory Drug Sales Value, 2020-2031
  • 5.5.2 Europe Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Respiratory Drug Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Respiratory Drug Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Respiratory Drug Sales Value, 2020-2031
  • 5.7.2 South America Respiratory Drug Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Respiratory Drug Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Respiratory Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Respiratory Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Respiratory Drug Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Respiratory Drug Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Respiratory Drug Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Respiratory Drug Sales Value, 2020-2031
  • 6.3.2 United States Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Respiratory Drug Sales Value, 2020-2031
  • 6.4.2 Europe Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Respiratory Drug Sales Value, 2020-2031
  • 6.5.2 China Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Respiratory Drug Sales Value, 2020-2031
  • 6.6.2 Japan Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Respiratory Drug Sales Value, 2020-2031
  • 6.7.2 South Korea Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Respiratory Drug Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Respiratory Drug Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Respiratory Drug Sales Value, 2020-2031
  • 6.9.2 India Respiratory Drug Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Respiratory Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 GSK
  • 7.1.1 GSK Company Information
  • 7.1.2 GSK Introduction and Business Overview
  • 7.1.3 GSK Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 GSK Respiratory Drug Product Offerings
  • 7.1.5 GSK Recent Development
• 7.2 AstraZeneca
  • 7.2.1 AstraZeneca Company Information
  • 7.2.2 AstraZeneca Introduction and Business Overview
  • 7.2.3 AstraZeneca Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 AstraZeneca Respiratory Drug Product Offerings
  • 7.2.5 AstraZeneca Recent Development
• 7.3 Boehringer Ingelheim
  • 7.3.1 Boehringer Ingelheim Company Information
  • 7.3.2 Boehringer Ingelheim Introduction and Business Overview
  • 7.3.3 Boehringer Ingelheim Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Boehringer Ingelheim Respiratory Drug Product Offerings
  • 7.3.5 Boehringer Ingelheim Recent Development
• 7.4 Vertex
  • 7.4.1 Vertex Company Information
  • 7.4.2 Vertex Introduction and Business Overview
  • 7.4.3 Vertex Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Vertex Respiratory Drug Product Offerings
  • 7.4.5 Vertex Recent Development
• 7.5 Roche
  • 7.5.1 Roche Company Information
  • 7.5.2 Roche Introduction and Business Overview
  • 7.5.3 Roche Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Roche Respiratory Drug Product Offerings
  • 7.5.5 Roche Recent Development
• 7.6 Novartis
  • 7.6.1 Novartis Company Information
  • 7.6.2 Novartis Introduction and Business Overview
  • 7.6.3 Novartis Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Novartis Respiratory Drug Product Offerings
  • 7.6.5 Novartis Recent Development
• 7.7 Teva
  • 7.7.1 Teva Company Information
  • 7.7.2 Teva Introduction and Business Overview
  • 7.7.3 Teva Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Teva Respiratory Drug Product Offerings
  • 7.7.5 Teva Recent Development
• 7.8 Chiesi
  • 7.8.1 Chiesi Company Information
  • 7.8.2 Chiesi Introduction and Business Overview
  • 7.8.3 Chiesi Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Chiesi Respiratory Drug Product Offerings
  • 7.8.5 Chiesi Recent Development
• 7.9 Mylan
  • 7.9.1 Mylan Company Information
  • 7.9.2 Mylan Introduction and Business Overview
  • 7.9.3 Mylan Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Mylan Respiratory Drug Product Offerings
  • 7.9.5 Mylan Recent Development
• 7.10 Sumitomo Dainippon
  • 7.10.1 Sumitomo Dainippon Company Information
  • 7.10.2 Sumitomo Dainippon Introduction and Business Overview
  • 7.10.3 Sumitomo Dainippon Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Sumitomo Dainippon Respiratory Drug Product Offerings
  • 7.10.5 Sumitomo Dainippon Recent Development
• 7.11 Merck
  • 7.11.1 Merck Company Information
  • 7.11.2 Merck Introduction and Business Overview
  • 7.11.3 Merck Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Merck Respiratory Drug Product Offerings
  • 7.11.5 Merck Recent Development
• 7.12 Beximco
  • 7.12.1 Beximco Company Information
  • 7.12.2 Beximco Introduction and Business Overview
  • 7.12.3 Beximco Respiratory Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Beximco Respiratory Drug Product Offerings
  • 7.12.5 Beximco Recent Development

8 Industry Chain Analysis

• 8.1 Respiratory Drug Industrial Chain
• 8.2 Respiratory Drug Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Respiratory Drug Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Respiratory Drug Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer